Who are olmesartan medoxomil+probenecid's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/olmesartan-medoxomil-probenecid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

olmesartan medoxomil+probenecid — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

olmesartan medoxomil+probenecid (olmesartan medoxomil+probenecid) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker + uricosuric agent. Area: Cardiovascular; Rheumatology.

marketed Angiotensin II receptor blocker + uricosuric agent AT1 receptor (angiotensin II type 1 receptor); uric acid transporter (URAT1) Cardiovascular; Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

olmesartan medoxomil+probenecid (olmesartan medoxomil+probenecid) — Central South University. Olmesartan medoxomil blocks angiotensin II receptors to lower blood pressure, while probenecid inhibits uric acid reabsorption in the kidney to reduce serum uric acid levels.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
olmesartan medoxomil+probenecid TARGET	olmesartan medoxomil+probenecid	Central South University	marketed	Angiotensin II receptor blocker + uricosuric agent	AT1 receptor (angiotensin II type 1 receptor); uric acid transporter (URAT1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker + uricosuric agent class)

Central South University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). olmesartan medoxomil+probenecid — Competitive Intelligence Brief. https://druglandscape.com/ci/olmesartan-medoxomil-probenecid. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab